Hologic revenues in women's healthcare jump
Second quarter fiscal 2004 revenues for Hologic totaled $55.6 million, an 11% increase compared with revenues of $50.3 million in the second quarter of fiscal 2003. For the quarter ended March 27, 2004, the company reported net income of $2.6 million
Second quarter fiscal 2004 revenues for Hologic totaled $55.6 million, an 11% increase compared with revenues of $50.3 million in the second quarter of fiscal 2003. For the quarter ended March 27, 2004, the company reported net income of $2.6 million compared with net income of $344,000 in the year-earlier period. Company execs attributed the improvement in earnings to decreasing expenses associated with the company's planned reduction of its general radiography systems business and to increased revenues, which came largely from the continuing sales shift from film-based mammography products to the higher margin Selenia full-field digital mammography system.
During the current quarter, Hologic installed and recognized as revenue 35 Selenia systems, which drove a 40% increase in mammography revenues to $27.9 million. As of the end of the quarter, 74 of these units valued at $53 million were on back order. Digital detector sales contributed further, generating $3 million, up 34% from the year-earlier period. Revenues were down 10%, however, for equipment related to osteoporosis assessment, as company sales tallied just $16.5 million of this equipment compared with $18.5 million in 2Q 2004.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
